{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:54:42Z","timestamp":1789188882983,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.canlet.2021.11.014","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T01:54:15Z","timestamp":1637027655000},"page":"352-362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Jolkinolide B sensitizes bladder cancer to mTOR inhibitors via dual inhibition of Akt signaling and autophagy"],"prefix":"10.1016","volume":"526","author":[{"given":"Jun","family":"Sang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Feng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Jun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-Zhu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Luo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Hua","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.11.014_bib1","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.drudis.2019.05.030","article-title":"Revisiting mTOR inhibitors as anticancer agents","volume":"24","author":"Teng","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.canlet.2021.11.014_bib2","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","article-title":"mTOR signalling and cellular metabolism are mutual determinants in cancer","volume":"18","author":"Mossmann","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2021.11.014_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.06.004","article-title":"Targeting the genetic alterations of the PI3K\u2013AKT\u2013mTOR pathway: its potential use in the treatment of bladder cancers","volume":"145","author":"Hou\u00e9d\u00e9","year":"2015","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.canlet.2021.11.014_bib4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11684-020-0812-7","article-title":"mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?","volume":"15","author":"Sun","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.canlet.2021.11.014_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","article-title":"Mechanisms of mTOR inhibitor resistance in cancer therapy","volume":"6","author":"Carew","year":"2011","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.canlet.2021.11.014_bib6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","article-title":"mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","volume":"1","author":"Rodrik-Outmezguine","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2021.11.014_bib7","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/bjc.2013.505","article-title":"PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K\/Akt activation","volume":"109","author":"Seront","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2021.11.014_bib8","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.4161\/auto.29119","article-title":"Combined MTOR and autophagy inhibition","volume":"10","author":"Rangwala","year":"2014","journal-title":"Autophagy"},{"key":"10.1016\/j.canlet.2021.11.014_bib9","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2147\/DDDT.S95900","article-title":"Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells","volume":"10","author":"lin","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.canlet.2021.11.014_bib10","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41419-020-03153-x","article-title":"Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy","volume":"11","author":"Guan","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2021.11.014_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1476-4598-11-85","article-title":"Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells","volume":"11","author":"Grabinski","year":"2012","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2021.11.014_bib12","doi-asserted-by":"crossref","first-page":"ra81","DOI":"10.1126\/scisignal.2001017","article-title":"Akt and autophagy cooperate to promote survival of drug-resistant glioma","volume":"3","author":"Fan","year":"2010","journal-title":"Sci. Signal."},{"key":"10.1016\/j.canlet.2021.11.014_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.clgc.2013.11.016","article-title":"Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer","volume":"12","author":"Sonpavde","year":"2014","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.canlet.2021.11.014_bib14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrurol.2011.144","article-title":"Urothelial carcinoma of the bladder: definition, treatment and future efforts","volume":"8","author":"Prasad","year":"2011","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.canlet.2021.11.014_bib15","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/labinvest.2010.133","article-title":"Expanding therapeutic targets in bladder cancer: the PI3K\/Akt\/mTOR pathway","volume":"90","author":"Ching","year":"2010","journal-title":"Lab. Invest."},{"key":"10.1016\/j.canlet.2021.11.014_bib16","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1007\/s12032-012-0216-x","article-title":"A phase II trial of temsirolimus in second-line metastatic urothelial cancer","volume":"29","author":"Gerullis","year":"2012","journal-title":"Med. Oncol."},{"key":"10.1016\/j.canlet.2021.11.014_bib17","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1093\/annonc\/mds057","article-title":"Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers","volume":"23","author":"Seront","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2021.11.014_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.canlet.2021.03.030","article-title":"Jolkinolide B targets thioredoxin and glutathione systems to induce ROS-mediated paraptosis and apoptosis in bladder cancer cells","volume":"509","author":"Sang","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2021.11.014_bib19","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1073\/pnas.1908158117","article-title":"High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model","volume":"117","author":"Luchtel","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2021.11.014_bib20","first-page":"1322","article-title":"Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells","volume":"1866","author":"Chiarini","year":"2019","journal-title":"BBA-Mol. Cell Res."},{"key":"10.1016\/j.canlet.2021.11.014_bib21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10059-011-0137-0","article-title":"Jolkinolide B from Euphorbia fischeriana Steud induces apoptosis in human leukemic U937 cells through PI3K\/Akt and XIAP Pathways","volume":"32","author":"Wang","year":"2011","journal-title":"Mol. Cells"},{"key":"10.1016\/j.canlet.2021.11.014_bib22","first-page":"1976","article-title":"Jolkinolide B induces apoptosis in MDA-MB-231 cells through inhibition of the PI3K\/Akt signaling pathway","volume":"27","author":"Lin","year":"2012","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2021.11.014_bib23","first-page":"223","article-title":"Jolkinolide A and Jolkinolide B inhibit proliferation of A549 cells and activity of human umbilical vein endothelial cells","volume":"23","author":"Shen","year":"2017","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res."},{"key":"10.1016\/j.canlet.2021.11.014_bib24","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1002\/jcb.26742","article-title":"Jolkinolide B inhibits glycolysis by downregulating hexokinase 2 expression through inactivating the Akt\/mTOR pathway in non-small cell lung cancer cells","volume":"119","author":"Gao","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.canlet.2021.11.014_bib25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3892\/or.2012.2113","article-title":"Jolkinolide B induces apoptosis in MCF-7 cells through inhibition of the PI3K\/Akt\/mTOR signaling pathway","volume":"29","author":"Xu","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2021.11.014_bib26","doi-asserted-by":"crossref","first-page":"114581","DOI":"10.1016\/j.jep.2021.114581","article-title":"Jolkinolide B inhibits proliferation or migration and promotes apoptosis of MCF-7 or BT-474 breast cancer cells by downregulating the PI3K-Akt pathway","volume":"282","author":"Wang","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.canlet.2021.11.014_bib27","first-page":"1066","article-title":"Paraptosis: mediation by MAP kinases and inhibition by AIP-1\/Alix, Cell Death","volume":"11","author":"Sperandio","year":"2004","journal-title":"Differ"},{"key":"10.1016\/j.canlet.2021.11.014_bib28","doi-asserted-by":"crossref","first-page":"101061","DOI":"10.1016\/j.redox.2018.11.019","article-title":"Curcuminoid B63 induces ROS-mediated paraptosis-like cell death by targeting TrxR1 in gastric cells","volume":"21","author":"Chen","year":"2019","journal-title":"Redox Biol"},{"key":"10.1016\/j.canlet.2021.11.014_bib29","doi-asserted-by":"crossref","first-page":"91223","DOI":"10.18632\/oncotarget.20077","article-title":"Jolkinolide B induces apoptosis of colorectal carcinoma through ROS-ER stress-Ca2+-mitochondria dependent pathway","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2021.11.014_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.canlet.2014.11.026","article-title":"Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K\/AKT pathway in human pancreatic cancer cells","volume":"357","author":"Li","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2021.11.014_bib31","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1080\/15548627.2016.1192751","article-title":"Inhibition of autophagosome-lysosome fusion by ginsenoside Ro via the ESR2-NCF1-ROS pathway sensitizes esophageal cancer cells to 5-fluorouracil-induced cell death via the CHEK1-mediated DNA damage checkpoint","volume":"12","author":"Zheng","year":"2016","journal-title":"Autophagy"},{"key":"10.1016\/j.canlet.2021.11.014_bib32","doi-asserted-by":"crossref","first-page":"101751","DOI":"10.1016\/j.redox.2020.101751","article-title":"Diclofenac impairs autophagic flux via oxidative stress and lysosomal dysfunction: implications for hepatotoxicity","volume":"37","author":"Jung","year":"2020","journal-title":"Redox Biol"},{"key":"10.1016\/j.canlet.2021.11.014_bib33","doi-asserted-by":"crossref","first-page":"15410","DOI":"10.1021\/acs.jmedchem.0c01449","article-title":"Development of potential antitumor agents from the scaffolds of plant-derived terpenoid lactones","volume":"63","author":"Ren","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2021.11.014_bib34","doi-asserted-by":"crossref","first-page":"652033","DOI":"10.3389\/fonc.2021.652033","article-title":"Natural phytochemicals in bladder cancer prevention and therapy","volume":"11","author":"Xia","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2021.11.014_bib35","first-page":"1","article-title":"Combination of rapamycin and resveratrol for treatment of bladder cancer","volume":"9999","author":"Alayev","year":"2016","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.canlet.2021.11.014_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bcp.2017.05.013","article-title":"OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma","volume":"140","author":"Peng","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2021.11.014_bib37","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.32213","article-title":"Selective eradication of cancer displaying hyperactive Akt by exploiting the metabolic consequences of Akt activation","volume":"7","author":"Nogueira","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.canlet.2021.11.014_bib38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.redox.2016.09.006","article-title":"Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer","volume":"10","author":"Chen","year":"2016","journal-title":"Redox Biol"},{"key":"10.1016\/j.canlet.2021.11.014_bib39","first-page":"172","article-title":"Cisplatin resistance: preclinical findings and clinical implications","volume":"1806","author":"K\u00f6berle","year":"2010","journal-title":"BBA-Rev Cancer"},{"key":"10.1016\/j.canlet.2021.11.014_bib40","doi-asserted-by":"crossref","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: the first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.canlet.2021.11.014_bib41","first-page":"188338","article-title":"The emerging role of paraptosis in tumor cell biology: perspectives for cancer prevention and therapy with natural compounds","volume":"1873","author":"Fontana","year":"2020","journal-title":"BBA-Rev. Cancer"},{"key":"10.1016\/j.canlet.2021.11.014_bib42","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pharmthera.2016.01.003","article-title":"Paraptosis in the anti-cancer arsenal of natural products","volume":"162","author":"Lee","year":"2016","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.canlet.2021.11.014_bib43","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nrurol.2011.135","article-title":"Reactive oxygen species-mediated therapeutic control of bladder cancer","volume":"8","author":"Wang","year":"2011","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.canlet.2021.11.014_bib44","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2021.11.014_bib45","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521005814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521005814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:02:43Z","timestamp":1759593763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521005814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":45,"alternative-id":["S0304383521005814"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.11.014","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Jolkinolide B sensitizes bladder cancer to mTOR inhibitors via dual inhibition of Akt signaling and autophagy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}